10/2019. UROMUNE (MV140) in BMC Infectious Diseases
The results of a retrospective clinical study carried out with Uromune (MV140), a mucosal (sublingual) bacterial spray vaccine, have been published.
The study, published in the BMC Infectious Diseases, addressed the efficacy of Uromune for the prevention of recurrent uncomplicated urinary tract infections, a condition that has considerable morbidity throughout the world and affects mainly women. The results, obtained in 784 patients, 648 women and 136 men, with documented urine infections by urine culture, indicate a high clinical efficacy of Uromune, confirming previous studies.
The study, carried out in two hospitals in Barcelona, Spain (Hospital de Mataró and Hospital Moisés Broggi) between 2011 and 2017, concludes that Uromune is highly effective in reducing infectious episodes and could be the treatment of first choice for the prevention of recurrent uncomplicated urinary tract infections.
Uromune (MV140) has been developed and manufactured by INMUNOTEK.
